Results 151 to 160 of about 19,533 (266)

Kisspeptin as a test of hypothalamic dysfunction in pubertal and reproductive disorders

Andrology, EarlyView.
Abstract The hypothalamic–pituitary–gonadal axis is regulated by the gonadotropin‐releasing hormone pulse generator in the hypothalamus. This is comprised of neurons that secrete kisspeptin in a pulsatile manner to stimulate the release of GnRH, and, in turn, downstream gonadotropins from the pituitary gland, and subsequently sex steroids and ...
Aureliane C. S. Pierret, Aaran H. Patel, Elisabeth Daniels, Alexander N. Comninos, Waljit S. Dhillo, Ali Abbara   +5 more
wiley   +1 more source

What is the need for adrenalectomy in patients with congenital adrenal hyperplasia in the era of CRF1/ACTH inhibitors? [PDF]

Front Endocrinol (Lausanne)
Fedorova O, Falhammar H.
europepmc   +1 more source

Low testosterone levels in men at age 31 associates with future risk of prediabetes and type 2 diabetes: A birth cohort study

Andrology, EarlyView.
Abstract Objective We aimed to investigate the association of a low serum testosterone concentration with the risk of abnormal glucose metabolism (i.e., prediabetes and type 2 diabetes) in men at a 15‐year follow‐up. Study population and methods In a population birth cohort, men with low testosterone (testosterone < 12.1 nmol/L, n = 136) and normal ...
Tuomisto A, Pinola P, Pesonen P, Franks S, Martikainen H, Tapanainen JS, Niinimäki M, Morin‐Papunen L   +7 more
wiley   +1 more source

Androgen receptor expression in glioblastoma: molecular profiling and association with tumor burden. [PDF]

Mol Biol Rep
Liubych L, Hahn L, Hollnagel R, Streubel MK, Ailani D, Leppert J, Krenzlin H, Matschke J, Soltwedel C, Borgardt N, Behling S, Zemskova O, Ditz C, Gebauer N, Kebenko M, Keric N, Lapshyna O, Gemoll T, Carl C, Neumann A, Rades D, Löser A.   +21 more
europepmc   +1 more source

Muscle Strength and Power Changes With Gender‐Affirming Hormone Therapy

Andrology, EarlyView.
ABSTRACT Background Androgen receptors are highly expressed in upper body muscles, but changes in maximal muscle strength and power in major upper body muscles have not been investigated during gender‐affirming hormone therapy (GAHT). Objective To assess prospective changes in maximal muscle strength and muscle power from before and after 1 year of ...
Mathilde Kamp Nørlund, Jakob Lindberg Nielsen, Marianne Skovsager Andersen, Rikke Hjortebjerg, Laust Frisenberg Buhl, Anne Pernille Hermann, Camilla Viola Buskbjerg Palm, Tine Taulbjerg Kristensen, Jan Frystyk, Per Aagaard, Jonas Mathiesen, Dorte Glintborg, Louise Lehmann Christensen   +12 more
wiley   +1 more source

Androgen metabolism in prostate cancer: recent advances.

Endocrinology
Sharifi N.
europepmc   +1 more source

Androgen receptor activation promotes tumor progression in canine and human triple negative breast cancer cell lines. [PDF]

Front Vet Sci
Caceres S, Crespo B, Herrera M, de la Puente M, Diaz Del Arco C, Alonso-Diez A, Illera MJ, Illera JC.   +7 more
europepmc   +1 more source

Contact Activation Is Alleviated by Testosterone Replacement Therapy in Klinefelter Syndrome: Evidence of Hormonal and Metabolic Modulation

Andrology, EarlyView.
ABSTRACT Background Klinefelter syndrome is associated with a markedly increased risk of venous thrombosis. While hypogonadism and metabolic dysfunction are known contributors, the role of the contact activation system in Klinefelter syndrome remains unexplored.
Simon Chang, Claus H. Gravholt, Anne Skakkebæk, Anna‐Marie Bloch Münster, Yaseelan Palarasah   +4 more
wiley   +1 more source

Neoadjuvant Chemohormonal Therapy for Patients With Very-high Risk Localized Prostate Cancer in Clinical Stages T2 and T3a. [PDF]

In Vivo
Kikuchi D, Numakura K, Miyauchi K, Abe N, Ohtani M, Kobayashi S, Wada N.   +6 more
europepmc   +1 more source

A concept for a new approach to combined oral contraception from adolescence to perimenopause: Continuous use of the oral GnRH antagonist Relugolix and the fetal estrogen Estetrol

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
It is expected that the relugolix estetrol combination RE4W will enable women to control their fertility and prevent menstrual cycle related problems, while offering a smooth transition through perimenopause into the postmenopause and decrease the risk of breast cancer.
Herjan J. T. Coelingh Bennink, Karolina Afors, Luis Bahamondes, Alessandra Graziottin, Deborah Bateson, Teresa Bombas, Yutaki Osuga, Santiago Palacios, Carolyn L. Westhoff, Kristina Gemzell‐Danielsson   +9 more
wiley   +1 more source